{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:15:36Z","timestamp":1791908136673,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,12]]},"DOI":"10.7759\/cureus.69282","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T20:48:46Z","timestamp":1726174126000},"source":"Crossref","is-referenced-by-count":1,"title":["Brain Metastatic Prostate Adenocarcinoma: Avoiding Mistaken Identities"],"prefix":"10.7759","author":[{"given":"James A","family":"Knight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre N","family":"Ene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham H","family":"El Khouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin W","family":"Myint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"St Clair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2008.3","article-title":"Prostate cancer: genes, environment, immunity and the use of immunotherapy","volume":"11","author":"Karan D","year":"2008","unstructured":"Karan D, Thrasher JB, Lubaroff D. Prostate cancer: genes, environment, immunity and the use of immunotherapy. Prostate Cancer Prostatic Dis. 2008, 11:230-6. 10.1038\/pcan.2008.3","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.22.9575","article-title":"Epidemiology, etiology, diagnosis and treatment of prostate cancer","volume":"15","author":"Daniyal M","year":"2014","unstructured":"Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 2014, 15:9575-8. 10.7314\/apjcp.2014.15.22.9575","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(21)00182-8","article-title":"Natural history and staging of prostate cancer","volume":"11","author":"Whitmore Jr WF","year":"1984","unstructured":"Whitmore Jr WF. Natural history and staging of prostate cancer. Uro Clin North Am. 1984, 11:205-20. 10.1016\/S0094-0143(21)00182-8","journal-title":"Uro Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1552-6569.2012.00767.x","article-title":"Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis","volume":"24","author":"Hatzoglou V","year":"2014","unstructured":"Hatzoglou V, Patel GV, Morris MJ, et al.. Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. J Neuroimaging. 2014, 24:161-6. 10.1111\/j.1552-6569.2012.00767.x","journal-title":"J Neuroimaging"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197612)38:6%3C2583::AID-CNCR2820380652%3E3.0.CO;2-D","article-title":"Brain metastasis from prostatic carcinoma","volume":"38","author":"Catane R","year":"1976","unstructured":"Catane R, Kaufman J, West C, et al.. Brain metastasis from prostatic carcinoma. Cancer. 1976, 38:2583-7. 10.1002\/1097-0142(197612)38:6%3C2583::AID-CNCR2820380652%3E3.0.CO;2-D","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11522","article-title":"Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience","volume":"98","author":"Tremont-Lukats IW","year":"2003","unstructured":"Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience. Cancer. 2003, 98:363-8. 10.1002\/cncr.11522","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5324600","article-title":"The clinical, diagnostic, therapeutic, and prognostic characteristics of brain metastases in prostate cancer: a systematic review","volume":"2022","author":"Mirmoeeni S","year":"2022","unstructured":"Mirmoeeni S, Azari Jafari A, Shah M, Salemi F, Hashemi SZ, Seifi A. The clinical, diagnostic, therapeutic, and prognostic characteristics of brain metastases in prostate cancer: a systematic review. Prostate Cancer. 2022, 2022:5324600. 10.1155\/2022\/5324600","journal-title":"Prostate Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard CC","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, et al.. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016, 375:443-53. 10.1056\/NEJMoa1603144","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30003-5","article-title":"Alterations in homologous recombination repair genes in prostate cancer brain metastases","volume":"13","author":"Rodriguez-Calero A","year":"2022","unstructured":"Rodriguez-Calero A, Gallon J, Akhoundova D, et al.. Alterations in homologous recombination repair genes in prostate cancer brain metastases. Nat Commun. 2022, 13:2400. 10.1038\/s41467-022-30003-5","journal-title":"Nat Commun"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono J","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, et al.. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020, 382:2091-102. 10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo J","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, et al.. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020, 21:162-74. 10.1016\/S1470-2045(19)30684-9","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00505","article-title":"Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: results from the TAPUR study","volume":"7","author":"Yang ES","year":"2023","unstructured":"Yang ES, Halabi S, Rothe M, et al.. Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: results from the TAPUR study. JCO Precis Oncol. 2023, 7:e2200505. 10.1200\/PO.22.00505","journal-title":"JCO Precis Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal5148","article-title":"Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers","volume":"9","author":"Sun C","year":"2017","unstructured":"Sun C, Fang Y, Yin J, et al.. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017, 9:10.1126\/scitranslmed.aal5148","journal-title":"Sci Transl Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh A","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, et al.. The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015, 42:197-209. 10.1007\/s00259-014-2949-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber M","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, et al.. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015, 56:668-74. 10.2967\/jnumed.115.154153","journal-title":"J Nucl Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer T","year":"2016","unstructured":"Maurer T, Gschwend JE, Rauscher I, et al.. Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016, 195:1436-43. 10.1016\/j.juro.2015.12.025","journal-title":"J Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219501","article-title":"Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology","volume":"60","author":"Hope TA","year":"2019","unstructured":"Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019, 60:786-93. 10.2967\/jnumed.118.219501","journal-title":"J Nucl Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3922-y","article-title":"Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives","volume":"45","author":"Backhaus P","year":"2018","unstructured":"Backhaus P, Noto B, Avramovic N, et al.. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging. 2018, 45:860-77. 10.1007\/s00259-017-3922-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-020-00300-7","article-title":"Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings","volume":"20","author":"de Galiza Barbosa F","year":"2020","unstructured":"de Galiza Barbosa F, Queiroz MA, Nunes RF, et al.. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020, 20:23. 10.1186\/s40644-020-00300-7","journal-title":"Cancer Imaging"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.77","article-title":"Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer","volume":"28","author":"Queisser A","year":"2015","unstructured":"Queisser A, Hagedorn SA, Braun M, Vogel W, Duensing S, Perner S. Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. Mod Pathol. 2015, 28:138-45. 10.1038\/modpathol.2014.77","journal-title":"Mod Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/289249-brain-metastatic-prostate-adenocarcinoma-avoiding-mistaken-identities","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T20:48:49Z","timestamp":1726174129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/289249-brain-metastatic-prostate-adenocarcinoma-avoiding-mistaken-identities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.69282","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}